Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/19/2009CA2698990A1 Mitogen-activated protein kinase kinase kinase 14 (map3k14) polymorphisms as indicators of subject outcome in critically ill subjects
03/19/2009CA2698973A1 1- or 2-substituted artemisinin derivatives for increasing the in vivo biological activity of biologically active compounds
03/19/2009CA2698944A1 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
03/19/2009CA2698929A1 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
03/19/2009CA2698882A1 Pharmaceutical compositions for oral use for treating patients affected by obesity
03/19/2009CA2698864A1 Process for preparing thermosensitive (poly(ethylene oxide) poly(propylene oxide)) derivatives that can be used to functionalize chitosan
03/19/2009CA2698825A1 Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection
03/19/2009CA2698819A1 6-pyrimidinyl-pyrimid-2-one derivative
03/19/2009CA2698818A1 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
03/19/2009CA2698812A1 Drug carriers
03/19/2009CA2698808A1 Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
03/19/2009CA2698792A1 Vegfr inhibitors containing a zinc binding moiety
03/19/2009CA2698645A1 Medicinal agent for disease associated with epstein-barr virus, and method for screening of the medicinal agent
03/19/2009CA2698540A1 Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
03/19/2009CA2698471A1 Substituted 6-phenylnicotinic acids and the use thereof
03/19/2009CA2698371A1 Alkylsulfone derivatives
03/19/2009CA2698256A1 Inhibitors of janus kinases
03/19/2009CA2698248A1 F1f0-atpase inhibitors and related methods
03/19/2009CA2697752A1 Guanidine-containing compounds useful as muscarinic receptor antagonists
03/19/2009CA2697682A1 Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
03/19/2009CA2697399A1 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
03/19/2009CA2697189A1 Dosing regimen
03/19/2009CA2696948A1 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
03/19/2009CA2695517A1 Alkylsulfonyl-substituted thiazolide compounds
03/19/2009CA2692702A1 Tri-amino-pyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors
03/19/2009CA2691782A1 Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
03/18/2009EP2036980A1 Down regulation of gene expression using virus-like particles charged with nucleic acid
03/18/2009EP2036926A2 Single-chain, multiple antigen forming molecule, its manufacture and use
03/18/2009EP2036917A1 Novel aminoglycoside antibiotic
03/18/2009EP2036916A1 Composition for promoting the production of equol
03/18/2009EP2036909A1 Quaternary ammonium salt compounds of spirocyclopiperazines, preparation methods and uses thereof
03/18/2009EP2036906A1 Azaindoles as inhibitors of soluble adenylate cyclase
03/18/2009EP2036905A1 Pyridylisoxazole derivative
03/18/2009EP2036903A1 Potentiator of radiation therapy
03/18/2009EP2036902A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain
03/18/2009EP2036901A1 C-phenyl 1-thioglucitol compound
03/18/2009EP2036898A2 Method for manufacturing 1.3 dioxolane 2ones and carboxylic acid esters by transacylation under alkaline reaction conditions
03/18/2009EP2036896A1 Cyclic amine compound
03/18/2009EP2036895A1 Hsp90 inhibitor
03/18/2009EP2036894A1 Aurora inhibitor
03/18/2009EP2036893A1 Abl KINASE INHIBITOR
03/18/2009EP2036892A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them
03/18/2009EP2036891A2 Isoquinoline inhibitors of P38
03/18/2009EP2036890A1 Crystalline form (i) of lercanidipine hydrochloride
03/18/2009EP2036889A2 Substituted indoles and a method for the production and use thereof
03/18/2009EP2036888A1 Naphthyl-substituted sulfonamides
03/18/2009EP2036887A1 Novel 6-5 bicycic heterocyclic derivative and medical use thereof
03/18/2009EP2036886A1 Association between an anti-atherothrombotic and an angiotensin conversion enzyme inhibitor
03/18/2009EP2036882A1 Zwitterionic connections and their use
03/18/2009EP2036575A1 Pharmaceutical compositions for oral use for treating patients affected by obesity
03/18/2009EP2036567A2 Modulation of the P2Y2 receptor pathway
03/18/2009EP2036566A1 Use of 20(s)-protopanoxadiol in manufacture of antidepressants
03/18/2009EP2036565A1 Preparation for external application to skin containing triterpenic acid
03/18/2009EP2036564A1 The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
03/18/2009EP2036563A1 Use of dihydroimidazolones for the treatment of behavioural abnormalities in dogs
03/18/2009EP2036562A1 A1 adenosine receptor antagonist for preventing and treating tissue injury and sepsis associated with yersinia pestis infection
03/18/2009EP2036561A1 Agent for overcoming resistance to anti-cancer agent
03/18/2009EP2036560A1 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy
03/18/2009EP2036559A1 Novel tape preparation
03/18/2009EP2036558A2 Orally administrable opioid formulations having extended duration of effect
03/18/2009EP2036557A1 Antitumor agent for thyroid cancer
03/18/2009EP2036556A1 Piperidone derivatives and medical uses thereof
03/18/2009EP2036555A1 The use of derviate of pyridone for preventing and treating radioactive injury of lungs
03/18/2009EP2036554A1 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment for diabetes mellitus
03/18/2009EP2036553A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
03/18/2009EP2036552A1 Senescence inhibitor
03/18/2009EP2036551A1 Agent for improving muscle power
03/18/2009EP2036549A1 Novel Composition
03/18/2009EP2036548A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/18/2009EP2036547A2 Treatment for Attention-Deficit Hyperactivity Disorder
03/18/2009EP2036545A1 Aripiprazole tablets
03/18/2009EP2036544A1 Dosage form of powder agglomerates
03/18/2009EP2036542A1 Epidural administration of therapeutic compounds with sustained rate of release
03/18/2009EP2036540A2 Improved injectable dispersions of propofol
03/18/2009EP2036538A1 Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine
03/18/2009EP2036445A1 Nutraceutic preparation in powder form containing free plant sterols
03/18/2009EP2036444A1 Liquid nutraceutic preparation containing free plant sterols
03/18/2009EP2035575A2 Methods of treatment
03/18/2009EP2035573A1 Methods for identifying modulators of eoxin formation
03/18/2009EP2035448A2 Neuroactive fragments of app
03/18/2009EP2035441A1 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
03/18/2009EP2035436A1 Fused thiazole derivatives as kinase inhibitors
03/18/2009EP2035435A1 Novel lapachone compounds and methods of use thereof
03/18/2009EP2035434A1 Quinoline derivatives, their preparation, their use, and medicaments comprising them
03/18/2009EP2035433A1 Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
03/18/2009EP2035432A1 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
03/18/2009EP2035431A1 Pharmaceutical compounds
03/18/2009EP2035430A1 6h-benzofuro[3,2-c][1]benzopyran and [2]benzopyrano [4,3-b][1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage
03/18/2009EP2035429A1 FUSED [d]PYRIDAZIN-7-ONES
03/18/2009EP2035427A2 Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonist
03/18/2009EP2035426A1 Pyrazolopyrimidones
03/18/2009EP2035425A1 Amino- imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia.
03/18/2009EP2035424A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia.
03/18/2009EP2035423A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia
03/18/2009EP2035422A1 Pteridine derivatives and their use as cathespin inhibitors
03/18/2009EP2035421A1 2-ARYLPYRAZOLO[L,5-alpha]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA)
03/18/2009EP2035420A2 Kv1.5 potassium channel inhibitors
03/18/2009EP2035419A1 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists
03/18/2009EP2035418A1 Novel heteroaryl substituted benzoxazoles
03/18/2009EP2035417A1 Benzimidazoles and their use for the treatemnt of diabetes
1 ... 2821 2822 2823 2824 2825 2826 2827 2828 2829 2830 2831 2832 2833 2834 2835 2836 2837 2838 2839 2840 2841 ... 7860